IS7219A - Lyfjablanda sem inniheldur (R) -bíkalútamíð - Google Patents

Lyfjablanda sem inniheldur (R) -bíkalútamíð

Info

Publication number
IS7219A
IS7219A IS7219A IS7219A IS7219A IS 7219 A IS7219 A IS 7219A IS 7219 A IS7219 A IS 7219A IS 7219 A IS7219 A IS 7219A IS 7219 A IS7219 A IS 7219A
Authority
IS
Iceland
Prior art keywords
bicalutamide
pharmaceutical composition
composition containing
pharmaceutical
composition
Prior art date
Application number
IS7219A
Other languages
English (en)
Inventor
Kay Cahill Julie
Frances Bateman Nicola
Original Assignee
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Limited filed Critical Astrazeneca Uk Limited
Publication of IS7219A publication Critical patent/IS7219A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS7219A 2001-10-15 2004-04-14 Lyfjablanda sem inniheldur (R) -bíkalútamíð IS7219A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103424A SE0103424D0 (sv) 2001-10-15 2001-10-15 Pharmaceutical formulation
PCT/GB2002/004621 WO2003032950A1 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r) -bicalutamide

Publications (1)

Publication Number Publication Date
IS7219A true IS7219A (is) 2004-04-14

Family

ID=20285650

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7219A IS7219A (is) 2001-10-15 2004-04-14 Lyfjablanda sem inniheldur (R) -bíkalútamíð

Country Status (19)

Country Link
US (1) US20060058381A1 (is)
EP (1) EP1439823A1 (is)
JP (1) JP3639587B2 (is)
KR (1) KR20050035163A (is)
CN (1) CN1571658A (is)
AR (1) AR036877A1 (is)
BR (1) BR0213248A (is)
CA (1) CA2462219A1 (is)
CO (1) CO5580755A2 (is)
HU (1) HUP0401369A3 (is)
IL (1) IL161306A0 (is)
IS (1) IS7219A (is)
MX (1) MXPA04003520A (is)
NO (1) NO20041485L (is)
PL (1) PL368226A1 (is)
RU (1) RU2004115023A (is)
SE (1) SE0103424D0 (is)
WO (1) WO2003032950A1 (is)
ZA (1) ZA200402729B (is)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03007641A (es) * 2001-02-27 2003-12-04 Astrazeneca Ab Formulacion farmaceutica.
PT3366283T (pt) 2004-01-20 2021-12-02 Novartis Ag Formulação e processo de compressão direta
US20080161404A1 (en) * 2005-02-23 2008-07-03 Astrazeneca Ab Bicalutamide for Delivering Increasing Steady State Plasma Levels
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
CN101987086B (zh) * 2009-08-03 2012-07-18 北京化工大学 一种超细比卡鲁胺口服片剂及其制备方法
JP2014523445A (ja) * 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ，インク． 前立腺癌を処置するための新規な組成物及び方法
EP2895463A1 (en) 2012-09-11 2015-07-22 Medivation Prostate Therapeutics, Inc. Formulations of enzalutamide
EP2968370A4 (en) 2013-03-14 2016-09-21 Univ Maryland AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
AU2014306698A1 (en) 2013-08-12 2016-01-28 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
CN106999432A (zh) 2014-12-05 2017-08-01 阿拉贡药品公司 抗癌组合物
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629237A (en) * 1968-09-12 1971-12-21 Shinetsu Chemical Co Compositions useful as enteric coatings and method for preparing acid phthalates of cellulose ethers for them
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
EP0100172B1 (en) * 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
KR0182801B1 (ko) * 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
CA2181358A1 (en) * 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
MXPA03007641A (es) * 2001-02-27 2003-12-04 Astrazeneca Ab Formulacion farmaceutica.
ATE324886T1 (de) * 2001-04-02 2006-06-15 Astrazeneca Ab Feste arzneizusammensetzung enthaltend 4'-cyano- trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy- 2-methylpropiono- m toluidide und pvp

Also Published As

Publication number Publication date
ZA200402729B (en) 2005-01-13
HUP0401369A2 (hu) 2004-11-29
CN1571658A (zh) 2005-01-26
EP1439823A1 (en) 2004-07-28
HUP0401369A3 (en) 2006-05-29
CO5580755A2 (es) 2005-11-30
AR036877A1 (es) 2004-10-13
JP3639587B2 (ja) 2005-04-20
CA2462219A1 (en) 2003-04-24
PL368226A1 (en) 2005-03-21
KR20050035163A (ko) 2005-04-15
RU2004115023A (ru) 2005-04-10
IL161306A0 (en) 2004-09-27
SE0103424D0 (sv) 2001-10-15
WO2003032950A1 (en) 2003-04-24
JP2004521963A (ja) 2004-07-22
US20060058381A1 (en) 2006-03-16
MXPA04003520A (es) 2004-07-23
BR0213248A (pt) 2004-09-28
NO20041485L (no) 2004-04-13

Similar Documents

Publication Publication Date Title
EP1450824A4 (en) PHARMACEUTICAL COMPOSITION
IS2893B (is) Lyfjasamsetning sem inniheldur lantanefnasambönd
FI20011478A0 (fi) Farmaseuttinen koostumus
HK1072200A1 (en) Pro-micelle pharmaceutical compositions
GB0111597D0 (en) Pharmaceutical compositions
AU2003276549A8 (en) Pharmaceutical compositions containing a biguanide-glitazone combination
HUP0303163A3 (en) Tramadol-based pharmaceutical composition
GB0117057D0 (en) Pharmaceutical composition
IS7051A (is) Lyfjasamsetningar
EP1408896A4 (en) PHARMACEUTICAL COMPOSITION
GB0101225D0 (en) Pharmaceutical compounds
GB0101227D0 (en) Pharmaceutical compounds
IS7219A (is) Lyfjablanda sem inniheldur (R) -bíkalútamíð
GB0129117D0 (en) Pharmaceutical composition
GB0116107D0 (en) Pharmaceutical composition
GB0127805D0 (en) Pharmaceutical composition
GB0104752D0 (en) Pharmaceutical compositions
PL370037A1 (en) Pharmaceutical composition
IS6857A (is) Lyfjafræðileg samsetning sem innheldur sítalópram
GB2382302B (en) Pharmaceutical compositions
EE200300378A (et) Farmatseutiline kompositsioon
AU2002342940A8 (en) New pharmaceutical compounds
GB0125061D0 (en) Pharmaceutical composition
HU0103049D0 (en) Pharmaceutical composition
GB0126732D0 (en) Pharmaceutical compositions